- Home
- FAAS vs MNPR Comparison
FAAS vs MNPR Comparison
Compare FAAS & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- MNPR
- Stock Information
- Founded
- FAAS 2021
- MNPR 2014
- Country
- FAAS Indonesia
- MNPR United States
- Employees
- FAAS N/A
- MNPR N/A
- Industry
- FAAS
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- FAAS
- MNPR Health Care
- Exchange
- FAAS NYSE
- MNPR Nasdaq
- Market Cap
- FAAS 115.9M
- MNPR 113.5M
- IPO Year
- FAAS N/A
- MNPR 2019
- Fundamental
- Price
- FAAS $0.42
- MNPR $25.82
- Analyst Decision
- FAAS
- MNPR Strong Buy
- Analyst Count
- FAAS 0
- MNPR 3
- Target Price
- FAAS N/A
- MNPR $27.33
- AVG Volume (30 Days)
- FAAS 201.5K
- MNPR 101.2K
- Earning Date
- FAAS 09-17-2024
- MNPR 11-08-2024
- Dividend Yield
- FAAS N/A
- MNPR N/A
- EPS Growth
- FAAS N/A
- MNPR N/A
- EPS
- FAAS N/A
- MNPR N/A
- Revenue
- FAAS $57,730,593.00
- MNPR N/A
- Revenue This Year
- FAAS N/A
- MNPR N/A
- Revenue Next Year
- FAAS N/A
- MNPR N/A
- P/E Ratio
- FAAS N/A
- MNPR N/A
- Revenue Growth
- FAAS 38.16
- MNPR N/A
- 52 Week Low
- FAAS $0.40
- MNPR $1.55
- 52 Week High
- FAAS $13.99
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- FAAS 31.77
- MNPR 57.88
- Support Level
- FAAS $0.52
- MNPR $22.61
- Resistance Level
- FAAS $0.57
- MNPR $32.20
- Average True Range (ATR)
- FAAS 0.09
- MNPR 3.36
- MACD
- FAAS 0.01
- MNPR -0.03
- Stochastic Oscillator
- FAAS 4.44
- MNPR 47.01
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.